TY - JOUR
T1 - Neurofilament Light Chain Levels Are Predictive of Clinical Conversion in Radiologically Isolated Syndrome
AU - Rival, Manon
AU - Thouvenot, Eric
AU - De Terdonck, Lucile Du Trieu
AU - Laurent-Chabalier, Sabine
AU - Demattei, Christophe
AU - Uygunoglu, Ugur
AU - Castelnovo, Giovanni
AU - Cohen, Mikael
AU - Okuda, Darin T.
AU - Kantarci, Orhun H.
AU - Pelletier, Daniel
AU - Azevedo, Christina
AU - Marin, Philippe
AU - Lehmann, Sylvain
AU - Siva, Aksel
AU - Mura, Thibault
AU - Lebrun-Frenay, Christine
N1 - Funding Information:
The Article Processing Charge was funded by the CHU Nîmes.
Funding Information:
The study was funded by CHU de Nîmes and has also been supported by the University of Montpellier, the Centre National de la Recherche Scientifique (CNRS), the Institut National de la Santé et de la Recherche Médicale (INSERM), the Occitanie Region, the fondation pour l'aide à la recherche sur la Sclérose en Plaques (ARSEP Fondation), the Radiologically Isolated Syndrome Consortium (RISC), and the Société Francophone de la Sclérose en Plaques (SFSEP).
Funding Information:
M. Rival has nothing to disclose. E. Thouvenot has received honoraria, travel grants, or research grants from the following pharmaceutical companies: Actelion, Biogen, Genzyme, Merck Serono, Novartis, Roche, and Teva pharma. L. Du Trieu de Terdonck has nothing to disclose. S. Laurent-Chabalier has nothing to disclose. C. Demattei has nothing to disclose. U. Uygunoglu has nothing to disclose. G. Castelnovo has nothing to disclose. M. Cohen received personal fees from Biogen, Merck, Novartis, Roche, Alexion, Ad Scientiam, Teva, and Sanofi. D.T. Okuda received personal compensation for consulting and advisory services from Biogen, Celgene/Bristol Myers Squibb, EMD Serono, Genentech, Genzyme, Janssen Pharmaceuticals, Novartis, Osmotica Pharmaceuticals, RVL Pharmaceuticals, Inc., TG Therapeutics, and Viela Bio, Inc. and research support from Biogen and EMD Serono/Merck. Royalties received for intellectual property licensed by The Board of Regents of The University of Texas System. O.H. Kantarci has nothing to disclose. Daniel Pelletier has nothing to disclose. C. Azevedo has nothing to disclose. S. Lehmann has nothing to disclose. P. Marin has nothing to disclose. A. Siva has received honoraria for educational presentations internationally and at national meetings and symposia sponsored by Bayer-Schering AG; Merck-Serono; Teva-Turkey; Biogen Idec/Gen Pharma of Turkey and Genzyme and consultation fees or travel and registration coverage for attending several national or international congresses or symposia from Merck Serono, Novartis, Genzyme, and Roche. T. Mura has nothing to disclose. C. Lebrun-Frenay has participated in expert boards for Biogen, Novartis, Roche, and Genzyme in the last 5 years. Expert and Speaker honoraria are either declined or donated to the URRIS research unit, University Cote d’Azur, Nice, France. She did not receive any financial compensation for her participation in the scientific committee of the French MS Society, ARSEP, and ECTRIMS apart from travel expenses. Go to Neurology.org/NN for full disclosures.
Funding Information:
The study was funded by CHU de Nmes and has also been supported by the University of Montpellier, the Centre National de la Recherche Scientifique (CNRS), the Institut National de la Sant et de la Recherche Mdicale (INSERM), the Occitanie Region, the fondation pour aide - la recherche sur la Sclrose en Plaques (ARSEP Fondation), the Radiologically Isolated Syndrome Consortium (RISC), and the Socit Francophone de la Sclrose en Plaques (SFSEP)
Publisher Copyright:
© American Academy of Neurology.
PY - 2023/1/24
Y1 - 2023/1/24
N2 - Background and ObjectivesTo evaluate the predictive value of serum neurofilament light chain (sNfL) and CSF NfL (cNfL) in patients with radiologically isolated syndrome (RIS) for evidence of disease activity (EDA) and clinical conversion (CC).MethodssNfL and cNfL were measured at RIS diagnosis by single-molecule array (Simoa). The risk of EDA and CC according to sNfL and cNfL was evaluated using the Kaplan-Meier analysis and multivariate Cox regression models including age, spinal cord (SC) or infratentorial lesions, oligoclonal bands, CSF chitinase 3-like protein 1, and CSF white blood cells.ResultsSixty-one patients with RIS were included. At diagnosis, sNfL and cNfL were correlated (Spearman r = 0.78, p < 0.001). During follow-up, 47 patients with RIS showed EDA and 36 patients showed CC (median time 12.6 months, 1-86). When compared with low levels, medium and high cNfL (>260 pg/mL) and sNfL (>5.0 pg/mL) levels were predictive of EDA (log rank, p < 0.01 and p = 0.02, respectively). Medium-high cNfL levels were predictive of CC (log rank, p < 0.01). In Cox regression models, cNfL and sNfL were independent factors of EDA, while SC lesions, cNfL, and sNfL were independent factors of CC.DiscussioncNfL >260 pg/mL and sNfL >5.0 pg/mL at diagnosis are independent predictive factors of EDA and CC in RIS. Although cNfL predicts disease activity better, sNfL is more accessible than cNfL and can be considered when a lumbar puncture is not performed.Classification of EvidenceThis study provides Class II evidence that in people with radiologic isolated syndrome (RIS), initial serum and CSF NfL levels are associated with subsequent evidence of disease activity or clinical conversion.
AB - Background and ObjectivesTo evaluate the predictive value of serum neurofilament light chain (sNfL) and CSF NfL (cNfL) in patients with radiologically isolated syndrome (RIS) for evidence of disease activity (EDA) and clinical conversion (CC).MethodssNfL and cNfL were measured at RIS diagnosis by single-molecule array (Simoa). The risk of EDA and CC according to sNfL and cNfL was evaluated using the Kaplan-Meier analysis and multivariate Cox regression models including age, spinal cord (SC) or infratentorial lesions, oligoclonal bands, CSF chitinase 3-like protein 1, and CSF white blood cells.ResultsSixty-one patients with RIS were included. At diagnosis, sNfL and cNfL were correlated (Spearman r = 0.78, p < 0.001). During follow-up, 47 patients with RIS showed EDA and 36 patients showed CC (median time 12.6 months, 1-86). When compared with low levels, medium and high cNfL (>260 pg/mL) and sNfL (>5.0 pg/mL) levels were predictive of EDA (log rank, p < 0.01 and p = 0.02, respectively). Medium-high cNfL levels were predictive of CC (log rank, p < 0.01). In Cox regression models, cNfL and sNfL were independent factors of EDA, while SC lesions, cNfL, and sNfL were independent factors of CC.DiscussioncNfL >260 pg/mL and sNfL >5.0 pg/mL at diagnosis are independent predictive factors of EDA and CC in RIS. Although cNfL predicts disease activity better, sNfL is more accessible than cNfL and can be considered when a lumbar puncture is not performed.Classification of EvidenceThis study provides Class II evidence that in people with radiologic isolated syndrome (RIS), initial serum and CSF NfL levels are associated with subsequent evidence of disease activity or clinical conversion.
UR - http://www.scopus.com/inward/record.url?scp=85140562744&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85140562744&partnerID=8YFLogxK
U2 - 10.1212/NXI.0000000000200044
DO - 10.1212/NXI.0000000000200044
M3 - Article
C2 - 36280258
AN - SCOPUS:85140562744
SN - 2332-7812
VL - 10
JO - Neurology: Neuroimmunology and NeuroInflammation
JF - Neurology: Neuroimmunology and NeuroInflammation
IS - 1
M1 - e200044
ER -